The effects of lipid-lowering therapy on paraoxonase activities and their relationship with the oxidant-antioxidant system in patients with dyslipidemia

Coronary Artery Disease

Volumn 15, Issue 5, 2004, Pages 277-283

  Kural, Birgül Vanizor ^a   Örem, Cihan ^a   Uydu, Hüseyin A ^a   Alver, Ahmet ^a   Örem, Asim ^a,b  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Antioxidant capacity; Atorvastatin; Autoantibodies against oxidized low density lipoprotein; Dyslipidemia; Lipid peroxidation; Paraoxonase

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 4043072119     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000135221.32523.a1     Document Type: Article

References (42)

1. Sirtori RC, Calabresi L, Marchioli R, Rubins BH. Cardiovascular risk changes after lipid lowering mediations: are they predictable? Atherosclerosis 2000; 152:1-8.
2. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15:2073-2084.
3. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57:69-73.
4. Aviram M. Does paraoxonase play a role in susceptibillity to cardiovascular disease? Mol Med 1999; 50:381-386.
5. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423:57-60.
6. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. Clin Invest 1995; 96:2882-2891.
7. Karakaya A, İbiş S, Kural T, Köse SK, Karakaya AE. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 1999; 118:193-200.
8. Rodrigo L, Gil F, Pla HA. Identificaiton of two rat liver proteins with paraoxonase activity: biochemical evidence for the identity of paraoxonase and arylesterase. Chem Biol Interact 1999; 119/120:163-175.
9. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275:33435-33442.
10. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2000; 276:44444-44449.
11. Girona J, La Ville AE, Solá R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83:846-851.
12. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138:271-280.
13. Örem C, Örem A, Uydu HA, Çelik Ş, Erdöl C, Vanizor Kural B. The effects of lipid-lowering therapy on LDL auto-antibodies: relationship between LDL oxidation and plasma total antioxidant status. Coron Artery Dis 2002; 13:67-71.
14. Friedewald WT, Levry RI, Frederickson DS. Estimation of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:467-479.
15. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring antioxidant status in premature neonates. Clin Sci 1993; 34:407-412.
16. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 1987; 45:337-351.
17. Sclavons M, Cordonnier CM, Mailleux PM, Heller FR, Desager J, Harvengt CM. Fast separation of the three main plasma lipoprotein classes by ultracentrifugation using vertical rotor and multiple discontinuous density gradient. Clin Chim Acta 1985; 153:125-135.
18. Lowry OH, Rosenbrough NL, Farr AL, Randel RL. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193:265-275.
19. Azizi F, Rahmani M, Raiszadeh F, Solati M, Navab M. Association of lipids, lipoproteins, apolipoproteins and paraoxonase enzyme activity with premature coronary artery disease. Coron Artery Dis 2002; 13:9-16.
20. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ashola M, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193-199.
21. Paragh G, Seres I, Balogh Z, Varga I, Karpati I, Matyus J, et al. The serum paraoxonase activity in patients with choronic failure and hyperlipidemia. Nephron 1998; 80:166-170.
22. Mackness B, Mackness MI, Arrol S, Turkei W, Julier K, Abuasha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998; 139:341-349.
23. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160:425-432.
24. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003; 72:2877-2885.
25. Roy AC, Loke DF, Saha N, Viegas OA, Tay JS, Ratnam SS. Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study. Gynecol Obstet Invest 1994; 38:10-13.
26. Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women [abstract]. Metabolism: Clin Exp 2001; 3:319-324.
27. Senti M, Tomás M, Anglada R, Elosua R, Marrugat J, Covas MI. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Intern Med 2003; 14:178-184.
28. Schiavon R, Battaglia P, De fanti E, Fasolin A, Biasioli S, Targa L, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324:39-44.
29. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002; 164:179-185.
30. Tomás M, Sentý M, Garcýa-Faria F, Vila J, Torrents A, Covas M, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 20:2113-2119.
31. Mackness MI, Durrington PN, Ayup A, Mackness B. Low serum paraoxonase: a risk factor for atherosclerotic disease. Curr Opp Lipidol 1999; 119/120:389-397.
32. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 1999; 26:892-904.
33. Ali AB, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Rad Biol Med 2003; 34:824-829.
34. Kondo A, Muranaka Y, Ohta I, Notsu K, Manabe M, Kotani K, et al. Relationships between TG concentrations and LDL size evaluated by Malondialdehyde-modified LDL. Clin Chem 2001; 47:893-900.
35. Aviram M. Oxidized low density lipoprotein (ox-LDL) interaction with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 1996; 34:599-608.
36. Inoue T, Inoue K, Maeda H, Takayanagi K, Morooka S. Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients. Clin Chim Acta 2001; 305:115-121.
37. Li MK, Bok SH, Jeong TS, Moon SS, Lee SE, Park YB, et al. Supplementation of aringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol-fed rats. Bioorg Med Chem 2002; 10:2239-2244.
38. Mackness M, Bouiller A, Hennuyer N, Mackness B, Hall M, Tailleux A, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 2000; 269:232-236.
39. Díaz J, Céspedes V, Molina R, Sastre JF, Vilanova E, Carrera V. No-correlation between paraoxonase activity and HDL levels in human serum in a local population. Toxicol Lett 1996; 88:28-29.
40. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998; 31:329-336.
41. La Du BN, Novais J. Human serum organophosphatase: biochemical characteristics and polymorphic inheritance. In: Reiner E, Aldrige WN, Hosking FCG (editors): Enzymes hydrolysing organophosphorous compounds. Chichester: Ellis-Horwood; 1989. pp. 41-52.
42. DelColle R, De Fanti E, Turazzini M, Battaglia P, Silvestri M, Targa L, et al. Serum paraoxonase activity is an independent risk factor for stroke: comparison with homocystein, fibrinogen and lipoprotein parameters. J Neurol Sci 1997; 150:S84.